In vivo studies using the CD11b-HSVTK/ganciclovir model (a syngeneic system involving intracranial implantation of GL261 glioma cells into mice, engineered to express herpes simplex virus thymidine kinase (HSV-TK) under the CD11b promoter) provided further validation. This evidence concerns the gene ITGAM and glioma.